|
| 37978284 | The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. | Nat Med | 2024 |
| 38039965 | A road map for the treatment of pediatric diffuse midline glioma. | Cancer Cell | 2024 |
| 37978284 | The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. | Nat Med | 2024 |
| 38039965 | A road map for the treatment of pediatric diffuse midline glioma. | Cancer Cell | 2024 |
| 36609372 | Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review. | J Neurosurg Pediatr | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 37046110 | First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. | J Neurooncol | 2023 |
| 36609372 | Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review. | J Neurosurg Pediatr | 2023 |
| 37526549 | Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). | Neuro Oncol | 2023 |
| 37526549 | Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). | Neuro Oncol | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 37046110 | First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. | J Neurooncol | 2023 |
| 34347089 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. | Neuro Oncol | 2022 |
| 36068285 | Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors. | NPJ Precis Oncol | 2022 |
| 35852795 | Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. | Clin Cancer Res | 2022 |
| 34347089 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. | Neuro Oncol | 2022 |
| 35307742 | Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. | Neuro Oncol | 2022 |
| 34668975 | Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. | Neuro Oncol | 2022 |
| 35148393 | Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. | Neuro Oncol | 2022 |
| 35852795 | Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. | Clin Cancer Res | 2022 |
| 36068285 | Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors. | NPJ Precis Oncol | 2022 |
| 35307742 | Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. | Neuro Oncol | 2022 |
| 35148393 | Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. | Neuro Oncol | 2022 |
| 34668975 | Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. | Neuro Oncol | 2022 |
| 34433654 | Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF[V600E]-Mutant Human Glioma. | Clin Cancer Res | 2021 |
| 33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | Neuro Oncol | 2021 |
| 34433654 | Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF[V600E]-Mutant Human Glioma. | Clin Cancer Res | 2021 |
| 33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | Neuro Oncol | 2021 |
| 32393959 | Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. | Neuro Oncol | 2020 |
| 32010615 | Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings. | Front Oncol | 2020 |
| 32404202 | Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets. | Acta Neuropathol Commun | 2020 |
| 32055852 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. | Neuro Oncol | 2020 |
| 32393959 | Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. | Neuro Oncol | 2020 |
| 33037266 | Robust deep learning classification of adamantinomatous craniopharyngioma from limited preoperative radiographic images. | Sci Rep | 2020 |
| 32523649 | Phase I study of vemurafenib in children with recurrent or progressive BRAF<sup>V600E</sup> mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). | Oncotarget | 2020 |
| 32502457 | Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2020 |
| 32552173 | Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. | J Child Neurol | 2020 |
| 32055852 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. | Neuro Oncol | 2020 |
| 32010615 | Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings. | Front Oncol | 2020 |
| 33037266 | Robust deep learning classification of adamantinomatous craniopharyngioma from limited preoperative radiographic images. | Sci Rep | 2020 |
| 32552173 | Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. | J Child Neurol | 2020 |
| 32502457 | Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2020 |
| 32523649 | Phase I study of vemurafenib in children with recurrent or progressive BRAF<sup>V600E</sup> mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). | Oncotarget | 2020 |
| 32404202 | Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets. | Acta Neuropathol Commun | 2020 |
| 30861105 | A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. | Int J Cancer | 2019 |
| 30861105 | A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. | Int J Cancer | 2019 |
| 31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | Lancet Oncol | 2019 |
| 31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | Lancet Oncol | 2019 |
| 29090526 | A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. | Pediatr Blood Cancer | 2018 |
| 30322880 | Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. | Clin Cancer Res | 2018 |